Rallybio Corp (RLYB)
Rallybio Corp is a clinical-stage biotechnology company focused on developing and commercializing therapies for patients with severe and rare diseases. Its pipeline includes RLYB116, an inhibitor of complement component 5 (C5) that has completed a phase 1 trial for diseases linked to complement dysregulation, and RLYB332, a preclinical antibody being studied for severe anemia with ineffective erythropoiesis and iron overload. The company also maintains a strategic alliance with AbCellera to discover, develop, and commercialize antibody-based therapeutics for rare diseases, along with a collaboration with Johnson & Johnson aimed at therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio was founded in 2018 and is headquartered in New Haven, Connecticut.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RLYB
|
$14.73
|
-12.1% Downside
|
Fair
|
$8
|
-52.3% Downside
|
Expensive
|
Good
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-11.4x
|
1.8x
|
104.1x
|
88.532 M
|
42.712 M
|
0.2%
|
14.8%
|
4.0
|
—
|
352.9%
|
